0 patents currently held, every record listed here
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
This portfolio holds none of the 6 US patents in force on its record. from the record
Of the 6 now held by other companies, 3 name Medicis Pharmaceutical Corporation as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end
When these terms end
Each bar runs from grant to computed term end. 2011 to 2032.
US 11,202,752
Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis with Shorter Durations of Imiquimod Therapy
Feb 8, 2028
US 8,299,109
Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream
no later than Dec 11, 2029
US 9,072,876
Pump Systems and Methods for Storing and Dispensing a Plurality of Precisely Measured Unit-Doses of Imiquimod Cream
Jun 17, 2032
201520192023202720312032
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Dec 2029 · Low confidence
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Medicis Pharmaceutical Corporation
Also notable
Ends Aug 2029 · High confidence
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2029.
now held by Thirona Bio, Inc.
Also notable
Ends Jun 2032 · High confidence
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2032.
now held by Medicis Pharmaceutical Corporation
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first.
Also on record: 6 patents in force now held by others · 27 patents ended · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
21 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.